Biodesix (NASDAQ:BDSX – Get Free Report) and Premier (NASDAQ:PINC – Get Free Report) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, institutional ownership and profitability.
Institutional & Insider Ownership
21.0% of Biodesix shares are owned by institutional investors. Comparatively, 74.4% of Premier shares are owned by institutional investors. 30.1% of Biodesix shares are owned by insiders. Comparatively, 1.0% of Premier shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Analyst Ratings
This is a summary of recent ratings for Biodesix and Premier, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Biodesix | 1 | 1 | 4 | 0 | 2.50 |
| Premier | 1 | 7 | 0 | 0 | 1.88 |
Volatility and Risk
Biodesix has a beta of 0.98, meaning that its stock price is 2% less volatile than the S&P 500. Comparatively, Premier has a beta of 0.64, meaning that its stock price is 36% less volatile than the S&P 500.
Valuation and Earnings
This table compares Biodesix and Premier”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Biodesix | $71.32 million | 0.80 | -$42.93 million | ($5.80) | -1.34 |
| Premier | $1.01 billion | 2.30 | $20.27 million | $0.22 | 128.23 |
Premier has higher revenue and earnings than Biodesix. Biodesix is trading at a lower price-to-earnings ratio than Premier, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Biodesix and Premier’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Biodesix | -53.66% | -269.67% | -43.94% |
| Premier | 2.00% | 7.04% | 3.75% |
Summary
Premier beats Biodesix on 9 of the 14 factors compared between the two stocks.
About Biodesix
Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR and NGS, and VeriStrat tests, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to establish the patient's prognosis and help guide treatment decisions. In addition, the company, through its partnership with Bio-Rad Laboratories, Inc., provides Bio-Rad SARS-CoV-2 ddPCR, a COVID-19 Test under Biodesix WorkSafe testing program; and Platelia SARS-CoV-2 Total Ab test, an antibody test for detecting a B-cell immune response to SARS-CoV-2 that indicate recent or prior infection. Further, it offers diagnostic and clinical research, as well as clinical trial testing services to biopharmaceutical companies; and discovers, develops, and commercializes companion diagnostics. The company was formerly known as Elston Technologies, Inc. and as changed to Biodesix, Inc. in 2006. Biodesix, Inc. was incorporated in 2005 and is headquartered in Louisville, Colorado.
About Premier
Premier, Inc., together with its subsidiaries, operates as a healthcare improvement company in the United States. It operates in two segments, Supply Chain Services and Performance Services. The Supply Chain Services segment offers its members with an access to a range of products and services, including medical and surgical products, pharmaceuticals, laboratory supplies, capital equipment, information technology, facilities and construction, and food and nutritional products, as well as purchased services, such as clinical engineering and workforce solutions. This segment also provides the ASCENDrive programs for members to receive group purchasing programs, tiers, and prices; SURPASS Performance Group services; and STOCKD, an e-commerce platform, as well as direct sourcing business; SaaS informatics products; supply chain co-management services; purchased services contracts; direct sourcing solutions; and supply chain resiliency programs. The Performance Services segment provides technology and services platform with offerings that help optimize performance in three main areas, including clinical intelligence, margin improvement, and value-based care under the PINC AI brand; third party administrator services and management of health benefit programs under the Contigo Health brand; and digital invoicing and payables services that offers financial support services to healthcare product suppliers and service providers under the Remitra brand. The company was incorporated in 2013 and is based in Charlotte, North Carolina.
Receive News & Ratings for Biodesix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biodesix and related companies with MarketBeat.com's FREE daily email newsletter.
